Abstract
Background and aims. The first direct-acting antivirals (DAAs) to treat the viral hepatitis C (HCV) became available in 2011. Despite numerous clinical studies of patient outcomes after treatment, few have evaluated changes in the liver microenvironment. Despite achieving sustained virologic response (SVR), patients may still experience adverse outcomes like cirrhosis and hepatocellular carcinoma. By comparing gene and protein expression in liver biopsies collected before and after treatment, we sought to determine whether specific signatures correlated with disease progression and adverse clinical outcomes. Methods. Biopsies were collected from 22 patients before and after DAA treatment. We measured ∼770 genes and used multispectral imaging with custom machine learning algorithms to analyze phenotypes of intrahepatic macrophages (CD68, CD14, CD16, MAC387, CD163) and T cells (CD3, CD4, CD8, CD45, FoxP3). Results. Before DAA treatment, patients showed two distinct gene expression patterns: one with high pro-inflammatory and antiviral gene expression and another with weaker expression. Patients with adverse outcomes exhibited significantly (p<0.05) more inflammatory activity and had more advanced fibrosis stages in their baseline biopsies than those with liver disease resolution. Patients who achieved SVR had significantly decreased liver enzymes, reduced inflammatory scores, and restored type 1 interferon pathways similar to controls. However, after DAA treatment, patients with persistently high gene expression (67%, pre-hot) still had significantly worse outcomes (p<0.049) despite achieving SVR. A persistent lymphocytic infiltrate was observed in a subset of these patients (76.5%). After therapy, anti-inflammatory macrophages (CD16+, CD16+CD163+, CD16+CD68+) increased, and T cell heterogeneity was more pronounced, showing a predominance of helper and memory T cells (CD3+CD45RO+, CD4+CD45RO+, CD3+CD4+CD45RO+). Conclusions. Patients who have more inflamed livers and more advanced fibrosis before DAA treatment should be closely followed for the development of adverse outcomes, even after achieving SVR. We can enhance patient risk stratification by integrating gene and protein expression profiles with clinical data. This could identify those who may benefit from more intensive monitoring or alternative therapeutic approaches, inspiring a new era of personalized patient care.
Lay Summary Direct-acting antiviral (DAA) therapy has dramatically improved the treatment of chronic HCV, making it curable for most people. This study determined gene and protein expression differences in the liver before and after treatment of HCV. These results will lead to a deeper understanding of the changes in the hepatic immune microenvironment with and without the virus present in the liver in hopes of improving patient surveillance, prognosis, and outcome in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors gratefully acknowledge the financial support provided by their grant funding sources. O.A.S., E.A, and H.L.S. were partially supported by an R01 from NIDDK (1R01DK125730-01A1-4). O.A.S. and H.S.L. were additionally supported by a Moody Endowment Grant (2014-07; LIME 19016). Preliminary optimization studies were partly funded by the National Center for Advancing Translational Services Clinical and Translational Science Awards Grant NCATS CTSA Grant KL2 Scholars Program (KL2TR001441-06). The acquisition of the Vectra 3 microscope was made possible through funding from the UT Systems Faculty Science and Technology Acquisition and Retention (STARs) Program. A.R. and S.K. were supported by CCSG Bioinformatics Shared Resource 5 P30 CA046592, a gift from Agilent Technologies, and a Precision Health Investigator award from U-M Precision Health. The NCI Grant R37-CA214955 partially supported S.K. and A.R. S.K. and A.R. were also partially supported by The University of Michigan (U-M) startup institutional research funds. S.K. and A.R. were also supported by a Research Scholar Grant from the American Cancer Society (RSG-16-005-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board approved this work at the University of Texas Medical Branch (IRB protocol #:13-0511).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data pertinent to this study are either included within the main article or provided as supplementary materials.
- HCV
- hepatitis C virus
- DAA
- direct-acting antiviral
- SVR
- sustained virologic response
- POST
- post-daa treatment
- PRE
- pre-daa treatment
- HCC
- hepatocellular carcinoma
- IFN
- interferon
- HIV
- human immunodeficiency virus
- UTMB
- university of Texas medical branch
- IRB
- institutional review board
- CAP
- college of American pathologist
- MHAI
- modified hepatitis activity index
- ALT
- alanine aminotransferase
- AST
- aspartate aminotransferase
- ALP
- alkaline phosphatase
- CLIA
- clinical laboratory improvement amendments
- FFPE
- formalin-fixed, paraffin-embedded
- RNA
- ribonucleic acid
- RCC
- resource compiler files
- PCA
- principal component analysis
- DEG
- differentially expressed genes
- ROIs
- regions of interest
- ANOVA
- analysis of variance
- DAPI
- 4′,6-diamidino-2-phenylindole
- JAK
- janus kinase
- STAT
- signal transducer and activation of transcription
- BMI
- body mass index
- TNF
- tumor necrosis factor
- TGFB
- transforming growth factor beta
- MHC
- major histocompatibility complex
- NKC
- natural killer cells
- ISG
- interferon-stimulated genes
- IFI
- interferon inducible protein
- MX
- mixovirus resistance
- TIFF
- tagged image file format
- H&E
- hematoxylin and eosin
- TSNE
- t-distributed stochastic neighbor embedding
- MAIT
- mucosal-associated invariant T cells
- HAART
- highly active antiretroviral therapy
- NLRP
- nucleotide-binding domain, leucine-rich-containing family, pyrin domain containing
- MASLD
- metabolic dysfunction-associated steatotic liver disease
- MASH
- metabolic dysfunction-associated steatohepatitis
- ESLD
- end-stage liver disease
- PT
- prothrombin time
- INR
- international normalized ratio
- BY
- Benjamini-Yekutieli
- STRING
- search tool for the retrieval of interacting genes/proteins
- FDR
- false discovery rates
- MCL
- Markov cluster algorithm
- pt
- patient
- AI
- artificial intelligence
